CLOs on the Move

Accredo Health Group

www.accredo.com

 
Headquartered in Memphis, Tennessee, Accredo Health Group, Inc., provides specialty pharmacy and related services for patients with certain complex and chronic conditions through our unique Therapeutic Resource Centers. Accredo is a wholly owned subsidiary of Express Scripts. Accredo’s Therapeutic Resource Centers are segmented by therapy and provide targeted therapy management programs for the following therapeutic areas: Rheumatoid arthritis Multiple sclerosis Oncology Hepatitis C Immune disorders Pulmonary arterial hypertension Hemophilia Other specialty therapies with dedicated care teams (RSV, growth deficiencies, etc.) Our services cover the range of needs posed by specialty pharmacy care. Our pharmacists and other healthcare professionals talk frequently with ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.accredo.com
  • 1640 Century Center Parkway
    Memphis, TN USA 38134
  • Phone: 877.222.7336

Executives

Name Title Contact Details

Similar Companies

Advanced Clinical Research Services

Advanced Clinical Research Services is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SecureChart

SecureChart is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ahura Scientific

Ahura Scientific is a Wilmington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shawnee Gardens

Shawnee Gardens Healthcare & Rehab Center is a healthcare facility that provides top quality medical care and skilled therapy in a newly renovated, state of the art facility.

Geron

We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.